术后采用人参皂甙Rg3联合丝裂霉素加呋喃尿嘧啶方案对进展期胃癌的疗效

目的探讨人参皂甙Rg3(Rg3)联合丝裂霉素加呋喃尿嘧啶(MF)化疗方案(Rg3 MF)对进展期胃癌术后的治疗效果。方法将71例进展期胃癌术后患者随机分为对照组(33例)和观察组(38例),前者用MF方案,后者用Rg3加MF方案治疗。检测血清血管内皮生长因子(VEGF)水平,并对预后进行对比分析。结果进展期胃癌患者血清VEGF含量[(297.8±129.6) pg/ml]明显高于正常组[(212.3±67.5)pg/ml](P<0.01),且与胃癌患者肿瘤的浸润深度、淋巴结转移、肿瘤大于4cm及TMN分期有关(均P<0.05)。术后14周时检测血清VEGF水平,观察组已明显低于术前(P<0.05)、而接近正常组水平,对照组仅降至术前水平。观察组、对照组中位生存时间分别为40和25个月。观察组的术后累计生存率高于对照组(P=0.047)。结论进展期胃癌患者术后采用MF方案联合Rg3治疗可明显降低血清VEGF含量,提高生存率。

Effect of adjuvant chemotherapy of ginsenoside Rg3 combined with mitomycin C and tegafur in advanced gastric cancer

OBJECTIVE: To evaluate the enhancing effects of ginsenoside Rg3 combined with mitomycin C and tegafur (MF) on postoperative chemotherapy in advanced gastric cancer. METHODS: Seventy-one postoperative patients with advanced gastric cancer were randomly divided into two groups, the control group (n=33), which received treatment with only MF (Mitomycin C+Tegafur), and the trial group (n=38), which were treated with ginsenoside Rg3+MF. The serum VEGF levels in the control group and trial group were detected preoperatively and postoperatively, meanwhile, the serum VEGF levels in 30 healthy persons were detected as comparison. The relations between patients survival and serum VEGF levels were analyzed. RESULTS: The levels of serum VEGF in advanced gastric cancer were higher than those in healthy persons [(297.8+/-129.6) pg/ml vs (212.3+/-67.5) pg/ml] (P<0.01), and were correlated with the depth of tumor invasion, lymph node metastasis, tumor size > 4 cm and TNM stage (P<0.05). Fourteen weeks after operation, the levels of serum VEGF in trial group decreased below those of preoperation and approached to normal range, while in the control group, the levels of serum VEGF decreased near those of preoperation only. The median survival of patients in trial group and control group were 40 and 25 months respectively. The survival rate of patients in trial group was significantly higher than that in control group (P=0.047). CONCLUSION: The combined application of ginsenoside Rg3+MF chemotherapy can decrease the concentration of serum VEGF and improve the survival rate in advanced gastric cancer patients.